Following on from the emergence of SGLT-2 inhibition for CKD, nsMRAs, and GLP-1 RAs have also recently demonstrated kidney and cardiovascular benefits effects in people with T2DM and CKD.11 This evidence concerns the gene SLC5A2 and chronic kidney disease.